As O
shown O
in O
, O
the O
responses O
of O
interfering O
peaks O
from O
blank O
were O
less O
than O
1% O
of O
that O
of O
Cer B-lipid
22:0;O2 I-lipid
and O
Cer B-lipid
24:0;O2 I-lipid
in O
LLOQ O
and O
less O
than O
1% O
of O
that O
of O
internal O
standards. O

PE O
(P-16 : 0/14 : 0) O
and O
FA B-lipid
18:1(9);(OH)2;OMe I-lipid
were O
all O
downregulated O
in O
the O
newly O
diagnosed O
T2DM O
group O
with O
fold O
changes O
at O
3.88 O
and O
2.65, O
respectively. O

LDLC, O
Low-Density O
Lipoprotein O
ST B-lipid
27:1;O; I-lipid
NIST, O
National O
Institute O
of O
Standards O
and O
Technology. O

Methionine O
(Met), O
C18:0e O
LPC, O
FA B-lipid
4:0;3OH I-lipid
and O
C42:3 O
SM O
were O
those O
with O
the O
highest O
negative O
coefficients, O
whereas O
linoleic O
acid, O
C40:6 O
PC O
and O
proline O
(Pro) O
were O
those O
with O
the O
highest O
positive O
coefficients. O

This O
observation O
may O
be O
due O
to O
the O
difference O
in O
the O
measured O
compounds O
between O
the O
two O
platforms: O
while O
Metabolon O
specifically O
quantifies O
the O
lysoPC O
with O
the O
20:4 O
fatty O
acid O
chain O
at O
sn1 O
position O
of O
the O
glycerol O
backbone O
(LPC O
20:4/0:0, I-lipid
Biocrates O
does O
not O
distinguish O
between O
the O
lysoPCs O
with O
fatty O
acid O
chains O
at O
sn1 O
and O
sn2 O
positions O
and O
only O
quantifies O
the O
sum O
concentration O
of O
the O
two O
forms O
(lysoPC(20:4/0:0 O
and O
LPC B-lipid
0:0/20:4. I-lipid

Moreover, O
serum O
levels O
of O
LPC B-lipid
18:2, I-lipid
PhePhe, O
uridine, O
taurine, O
L-threonine, O
and O
FA B-lipid
16:0;3OH I-lipid
were O
significantly O
correlated O
with O
disease O
activity O
scores O
(all O
p<0.05) O
in O
AOSD O
patients. O

Further O
information O
about O
spectral O
fragmentation O
patterns O
(MS/MS) O
of O
the O
PC B-lipid
18:1/20:3, I-lipid
PC B-lipid
18:1/22:5, I-lipid
PC B-lipid
18:1/22:6 I-lipid
and O
SM B-lipid
18:1;O2/18:2 I-lipid
is O
explained O
in O
detail O
as O
follows. O

α–KB O
is O
produced O
by O
amino O
acid O
catabolism O
(threonine O
and O
methionine) O
and O
glutathione O
anabolism O
(cysteine O
formation O
pathway) O
and O
is O
metabolized O
to O
CoA B-lipid
3:0 I-lipid
and O
carbon O
dioxide O
. O

Recently, O
Chang O
et O
al. O
demonstrate O
that O
medium-chain O
triglyceride, O
rich O
in O
FA B-lipid
10:0, I-lipid
provides O
an O
antiseizure O
effect O
acting O
through O
direct O
AMPA O
receptor O
inhibition. O

The O
level O
of O
PC B-lipid
15:0/16:0 I-lipid
was O
highest O
in O
GP O
group O
and O
lowest O
in O
PP O
group. O

HL-60 O
cells O
have O
been O
reported O
to O
possess O
this O
metabolic O
activity O
with O
respect O
to O
PGE2 O
and O
FA B-lipid
20:4;OH I-lipid
. O

While O
these O
higher O
amounts O
were O
most O
notable O
for O
FA B-lipid
20:4;OH I-lipid
and O
17-HDHA, O
even O
these O
differences O
were O
not O
significant. O

FA B-lipid
18:2 I-lipid
increased O
LPL O
and O
MCP-1 O
mRNA O
and O
protein, O
and O
this O
effect O
was O
prevented O
by O
pretreatment O
with O
2.5 O
μg/ml O
parthenolide, O
an O
NF-κB O
inhibitor O
(,) O
(A–D O
) O
(,). O

S2G O
); O
glycerophosphoserine O
38:4, O
PS B-lipid
20:4/18:0 I-lipid
at O
m O
/z O
810.6 O
(SI O
Appendix O
, O
Fig. O

Plasma O
and O
muscle O
concentrations O
of O
DG B-lipid
18:2_18:2 I-lipid
and O
6 O
TG O
species O
also O
correlated. O

The O
overweight O
group O
showed O
significant O
decreases O
in O
11 O
metabolites—lysoPCs O
containing O
C14:0, O
C16:1, O
C16:0, O
C17:0, O
C18:2, O
C18:1, O
C18:0, O
C20:4, O
C20:3, O
and O
C22:6 O
(Suppl. O
1), O
and O
PC O
(18:0/20:4)—and O
significant O
increases O
in O
6 O
metabolites—L-leucine, O
palmitic O
amide, O
L-octanoylcarnitine, O
decanoylcarnitine, O
PC B-lipid
18:2/18:2, I-lipid
and O
lactosylceramide. O

However, O
five O
of O
the O
metabolites O
(Lyso O
PC B-lipid
18:2, I-lipid
lactate, O
choline, O
lysine O
and O
asparagine) O
were O
not O
concordant O
across O
reported O
studies O
(Tables O
and O
). O

Besides, O
previous O
study O
employed O
fragment O
ion O
m/z O
281([M-H-H_2 O
O-CO_2 O
]-) O
to O
represent O
FA B-lipid
22:6;OH, I-lipid
yet, O
this O
water O
and O
CO_2 O
loss O
is O
common O
for O
all O
HDoHEs. O

Moreover, O
we O
found O
statistically O
significant O
positive O
correlations O
between O
the O
Lactate O
Dehydrogenase O
levels O
and O
the O
following O
metabolites: O
Octadecenoylcarnitine O
(r O
= O
0.41, O
p O
= O
0.044), O
FA B-lipid
22:6 I-lipid
(r O
= O
0.45, O
p O
= O
0.023), O
Symmetric O
dimethylarginine O
(r O
= O
0.46, O
p O
= O
0.022), O
and O
significant O
negative O
correlations O
with O
Valine O
(r O
= O
−0.41, O
p O
= O
0.043) O
and O
tripentadecanoate O
TG15 O
(r O
= O
−0.43, O
p O
= O
0.030) O
levels, O
among O
PC O
patients. O

Although O
this O
LOD O
was O
about O
5 O
times O
higher O
than O
that O
obtained O
from O
PIS O
m O
/z O
184 O
(phosphocholine O
head O
group O
ion) O
of O
protonated O
PC B-lipid
16:0/18:1 I-lipid
(Fig. O
S9b_† O
), O
it O
was O
significantly O
more O
sensitive O
than O
the O
use O
of O
formate O
or O
acetate O
anion O
adduct O
ions O
(Fig. O
S9c_† O
). O

, O
For O
instance, O
the O
sn O
-purity O
of O
the O
PC B-lipid
16:0/18:1 I-lipid
sample O
is O
93 O
± O
2%, O
meaning O
that O
it O
contains O
7 O
± O
2% O
PC B-lipid
18:1/16:0. I-lipid

Particularly, O
SM B-lipid
18:1;O2/24:0 I-lipid
was O
found O
to O
inversely O
correlate O
with O
MELD O
score, O
and O
positively O
correlate O
with O
inflammation O
grades O
in O
CHB O
patients; O
phytosphingosine O
and O
dihydrosphingosine O
were O
found O
to O
be O
decreased O
in O
the O
sera O
of O
HCC O
patients O
compared O
to O
cirrhosis O
patients. O

Plasma O
lipids O
specific O
to O
obesity‐related O
insulin O
resistance O
(i.e., O
different O
between O
OIS O
and O
OIR, O
but O
not O
between O
OIR O
and O
Lean) O
included O
DG B-lipid
14:1_16:0, I-lipid
SE B-lipid
27:1/22:4 I-lipid
and O
PC(O‐35:4) O
(higher) O
and O
Hex2Cer(d18:1/22:0), O
Hex2Cer(d18:1/24:0) O
and O
LPC B-lipid
22:0 I-lipid
(lower). O

Filled O
circles O
illustrate O
retention O
time O
of O
the O
authentic O
standards, O
PC B-lipid
18:1/18:1, I-lipid
PC B-lipid
18:0/20:4 I-lipid
and O
PC B-lipid
18:0/22:6, I-lipid
confirming O
the O
predicted O
pattern. O

The O
combination O
of O
FA B-lipid
5:0;4OH, I-lipid
5-dihydrotestosterone O
sulfate, O
serine, O
spermine, O
and O
xanthine O
distinguished O
OSA O
from O
SS O
with O
a O
sensitivity O
of O
85% O
and O
specificity O
of O
80%. O

FAL B-lipid
6:0, I-lipid
as O
well O
as O
other O
aldehydes, O
for O
instance, O
has O
been O
already O
reported O
by O
several O
authors O
as O
discriminant O
metabolites O
for O
LC. O

As O
a O
contrast, O
LC–PB–MS/MS O
offered O
high O
quality O
data O
for O
PE B-lipid
39:4 I-lipid
([_PB O
M+H]_+ O
, O
m/z O
840.4, O
Fig. ), O
from O
which O
four O
pairs O
of O
fragment O
ions O
could O
be O
picked O
out O
as O
C=C O
diagnostic O
ions O
(m/z O
453/479, O
493/519, O
533/559, O
and O
573/599). O

The O
m/z O
279.2329 O
as O
the O
base O
peak O
indicated O
that O
FA B-lipid
18:2 I-lipid
located O
at O
sn O
-2 O
position O
on O
the O
glycerol O
backbone, O
as O
it O
is O
known O
that O
fragment O
ion O
ratio O
of O
[FA_1 O
-H]_− O
/[FA_2 O
-H]_− O
is O
less O
than O
1 O
[, O
, O
]. O

LC-MRM-MS O
Chromatograms O
for O
19-HETE O
and O
FA B-lipid
20:4;OH I-lipid
at O
three O
different O
ratios O
in O
neat O
solution. O

Cluster O
2, O
comprised O
predominantly O
of O
C18-derived O
esterified O
diols O
(FA O
18:1;(OH)2, I-lipid
9,10- O
DiHOME, O
FA B-lipid
18:2;(OH)2, I-lipid
FA O
18:2;(OH)2), O
negatively O
correlated O
with O
VCAM-1 O
expression. O

A O
Kruskal-Wallis O
test O
of O
the O
individual O
time-points O
for O
each O
of O
the O
selected O
candidate O
markers O
revealed O
that O
most O
of O
them O
can O
be O
detected O
postprandially O
at O
more O
than O
one O
time-point O
between O
1 O
and O
6 O
h O
(lactose, O
galactose, O
galactitol, O
galactonate, O
galactono-1,5-lactone, O
methionine, O
proline, O
3-phenyllactic O
acid, O
FA B-lipid
12:0, I-lipid
linoleic O
acid, O
γ-tocopherol, O
maltol, O
sucrose, O
unknown O
S13, O
unknown O
S27), O
their O
presence O
in O
serum O
being O
no O
longer O
detected O
at O
24 O
h O
(Table O
S3). O

The O
model O
consistently O
showed O
that O
autism O
was O
associated O
with O
2 O
particular O
metabolites: O
sphingosine O
1-phosphate O
and O
FA B-lipid
22:6. I-lipid

 528.6; O
and O
PC B-lipid
40:2 I-lipid
at O
m/z O
= O
842.90. O

Lauric O
acid O
(C12:0), O
FA B-lipid
15:0 I-lipid
(C15:0), O
stearic O
acid O
(C18:0), O
myristoleic O
acid O
(C14:1), O
cis-10 O
FA O
15:0 O
(C15:1) O
and O
arachidonic O
acid O
(C20:4n6) O
showed O
the O
strongest O
metabolite-metabolite O
correlations O
among O
the O
TFAs O
in O
the O
case O
group, O
while O
age O
was O
not O
correlated O
to O
any O
of O
these O
metabolites O
in O
any O
group. O

In O
addition O
a O
decrease O
in O
TG B-lipid
52:1 I-lipid
was O
detected. O

The O
inter-run O
accuracy O
was O
−1.6%RE O
and O
1.3%RE O
for O
Cer B-lipid
22:0;O2 I-lipid
and O
Cer B-lipid
24:0;O2, I-lipid
respectively. O

Similarly, O
9 O
metabolites O
(Phytosphingosine, O
PC B-lipid
22:6, I-lipid
PE B-lipid
20:3, I-lipid
2-keto O
valericacid, O
Sphinganine-phosphate, O
Cholic O
acid, O
Deoxycholic O
acid, O
3-Methylxanthine/7-Methylxanthine/1-Methylxanthine, O
Uridine O
monophosphate) O
were O
selected O
from O
33 O
metabolites O
(heat-map O
displayed O
in O
) O
between O
T2DM O
and O
DACD O
patients. O

Previous O
lipidomics O
analyses O
(not O
in O
bvFTD) O
showed O
that O
a O
considerable O
number O
of O
TG O
and O
DG O
species O
were O
closely O
associated O
with O
dyslipidemia, O
and O
TG B-lipid
50:2, I-lipid
52:2, O
52:3, O
and O
52:4 O
were O
the O
most O
abundant O
species. O

Both O
valine O
and O
isoleucine O
are O
considered O
glucogenic, O
being O
metabolized O
to O
CoA B-lipid
3:0 I-lipid
and O
acetyl-CoA, O
respectively. O

Abbreviations: O
PSP: O
progressive O
supranuclear O
palsy; O
SDMA: O
symmetric O
dimethylarginine O
fatty O
acid; O
LPC B-lipid
16:0: I-lipid
lysophosphatidylcholine O
(16:0); O
AC: O
acylcarnitine. O

Guo O
et O
al O
. O
reported O
that O
different O
combinations O
of O
sphingomyelin O
(SM) O
(34:1), O
PC B-lipid
34:2, I-lipid
PC B-lipid
34:1, I-lipid
PC B-lipid
36:4, I-lipid
PC B-lipid
36:3, I-lipid
and O
PC B-lipid
36:2 I-lipid
exhibit O
high O
diagnostic O
potential O
for O
lung O
cancer, O
colorectal O
cancer, O
gastric O
cancer O
and O
pancreatic O
cancer. O

Accumulation O
of O
α–HB O
is O
postulated O
to O
occur O
in O
vivo O
when O
either O
(a) O
the O
formation O
of O
α–KB O
exceeds O
the O
rate O
of O
its O
catabolism, O
which O
leads O
to O
substrate O
accumulation, O
or O
(b) O
there O
is O
product O
inhibition O
of O
the O
dehydrogenase O
that O
catalyzes O
the O
conversion O
of O
α–KB O
to O
CoA B-lipid
3:0 I-lipid
, O
. O

Among O
these O
metabolites, O
the O
high O
level O
of O
C8-ceramide, O
palmitoylcarnitine, O
hypoxanthine, O
linoleamide, O
palmitic O
amide, O
methionine, O
sphingosine O
and O
inosine, O
and O
the O
low O
level O
of O
isoleucine, O
valine, O
glutamine, O
LPC B-lipid
18:2, I-lipid
LPC B-lipid
20:3 I-lipid
and O
LPC B-lipid
22:5 I-lipid
were O
observed O
in O
HAPE O
subjects O
relative O
to O
healthy O
controls. O

We O
further O
examined O
whether O
ovarian O
cancer O
homogenates O
produce O
higher O
levels O
of O
FA B-lipid
20:4;OH I-lipid
when O
incubated O
with O
AA O
as O
compared O
to O
normal O
tissue. O

Thus, O
FA B-lipid
20:5 I-lipid
(C20:5) O
and O
FA B-lipid
20:5;OH I-lipid
may O
become O
a O
potent O
biomarker O
for O
prediction O
LC O
development. O

The O
elevated O
plasma O
concentrations O
of O
FA B-lipid
20:4;OH I-lipid
in O
RVD O
occurred O
with O
decreased O
urinary O
excretion O
of O
FA O
20:4;OH O
and O
probably O
reflects O
the O
multiple O
pathways O
for O
disposition O
of O
FA O
20:4;OH, O
namely, O
incorporation O
of O
FA O
20:4;OH O
into O
phospholipids, O
ω O
- O
and O
β O
-oxidation, O
and O
transformation O
of O
FA O
20:4;OH O
via O
cyclooxygenase O
into O
prostaglandin O
analogs._, O

FA B-lipid
9:0;COOH I-lipid
is O
a O
dicarboxylic O
acid. O

Although O
it O
has O
been O
suggested O
that O
the O
sn O
-2 O
position O
is O
preferred O
by O
polyunsaturated O
acyl O
chains,, O
our O
data O
quantitatively O
show O
that O
many O
of O
them O
still O
consist O
of O
minor O
sn O
-isomers, O
such O
as O
PC B-lipid
20:4/16:0 I-lipid
(4%) O
and O
PC B-lipid
22:4/18:0 I-lipid
(9%). O

As O
a O
result, O
LPG B-lipid
20:5, I-lipid
as O
a O
potential O
biomarker, O
could O
provide O
an O
AUC O
value O
of O
0.736, O
significantly O
increasing O
the O
predictive O
power O
of O
clinical O
characteristics O
from O
AUC O
value O
0.739 O
to O
0.875 O
(Figure O
). O

Liquid O
chromatography/mass O
spectroscopy O
(LC–MS/MS) O
analysis O
revealed O
that O
ovary O
tumor O
samples O
showed O
increased O
synthesis O
of O
FA B-lipid
20:4;OH I-lipid
relative O
to O
what O
was O
observed O
for O
normal O
tissue O
samples. O

The O
urinary O
excretion O
of O
FA B-lipid
20:4;OH I-lipid
was O
reduced O
in O
patients O
with O
RVD O
whether O
expressed O
as O
micrograms O
per O
hour O
or O
when O
factored O
for O
urinary O
excretion O
of O
creatinine. O

Caprylic O
acid, O
also O
named O
FA B-lipid
8:0, I-lipid
is O
a O
medium-chain O
fatty O
acid O
which O
down-regulates O
a O
number O
of O
key O
adipogenic O
genes O
including O
peroxisome O
proliferator O
activated O
receptor O
(PPAR), O
CCAAT/enhancer O
binding O
protein O
alpha. O

Consistent O
with O
the O
the O
K-M O
survival O
result O
with O
only O
1 O
selected O
serum O
metabolite O
(FA O
6:2(2,4), I-lipid
4-methylphenyl O
dodecanoate O
or O
glycerol O
tributanoate O
alone) O
(Figure O
) O
(p O
<0.05), O
this O
might O
suggest O
that O
the O
3 O
selected O
serum O
metabolites O
(FA O
6:2(2,4), O
4-methylphenyl O
dodecanoate O
and O
glycerol O
tributanoate) O
can O
be O
considered O
to O
be O
useful O
prognostic O
factors O
for O
GC. O

In O
our O
lipidomics O
analysis, O
TG B-lipid
56:4 I-lipid
was O
the O
second O
most O
significantly O
increased O
TG O
species O
with O
a O
p O
value O
of O
0.0006. O

This O
is O
illustrated O
for O
PC B-lipid
38:4 I-lipid
in O
, O
which O
depicts O
the O
extraction O
chromatogram O
(EIC) O
of O
m/z O
810.597 O
and O
highlight O
the O
elution O
and O
peak O
shape O
of O
the O
4 O
identified O
isomers. O

To O
this, O
750 µl O
methyl O
tert-butyl O
ether O
(MTBE) O
was O
added, O
along O
with O
150 µl O
of O
internal O
standard O
mix, O
containing O
the O
following O
six O
internal O
standards: O
1,2-di-o-octadecyl-sn-glycero-3-phosphocholine O
(0.6 µM), O
1,2-di-O-phytanyl-sn-glycero-3-phosphoethanolamine O
(1.2 µM), O
C8-ceramide O
(0.6 µM), O
N-heptadecanoyl-D-erythro-sphingosylphosporylcholine O
(0.6 µM), O
FA B-lipid
11:0 I-lipid
(0.6 µM), O
and O
trilaurin O
(0.6 µM). O

There O
are O
also O
data O
showing O
that O
the O
P. O
falciparum O
apicoplast O
fraction O
contains O
low O
levels O
of O
the O
odd-chain O
fatty O
acid, O
C17:0, O
which O
could O
be O
synthesized O
by O
either O
the O
type O
II O
FAS O
complex O
or O
by O
fatty O
acid O
elongases O
using O
CoA B-lipid
3:0 I-lipid
instead O
of O
acetyl-CoA O
(Botté O
et O
al. O
). O

In O
tissues, O
we O
observed O
low O
levels O
of O
SM B-lipid
16:0;O2, I-lipid
PC B-lipid
32:0, I-lipid
PC B-lipid
38:4 I-lipid
and O
high O
levels O
of O
PC B-lipid
34:2, I-lipid
PC B-lipid
34:1, I-lipid
PC B-lipid
36:3 I-lipid
and O
PC B-lipid
36:2 I-lipid
in O
MF O
cancer O
areas O
compared O
to O
adjacent O
non-cancer O
areas O
(Figure O
). O

FA B-lipid
20:4;OH I-lipid
induced O
cell O
proliferation O
and O
DNA O
synthesis O
in O
vascular O
smooth O
muscle O
and O
proximal O
tubule O
cell O
cultures O
as O
well O
as O
angiogenic O
effects O
by O
stimulating O
endothelial O
cell O
proliferation, O
which O
was O
accompanied O
by O
increased O
vascular O
endothelial O
growth O
factor O
(VEGF) O
expression O
and O
release O
(, O
, O
). O

shows O
the O
highest O
calibrator O
(ULOQ, O
6/24 O
μg/mL O
of O
Cer B-lipid
22:0;O2/Cer I-lipid
24:0;O2) I-lipid
without O
internal O
standards, O
and O
the O
contribution O
from O
[M+4+H]_+ O
isotope O
peaks O
of O
Cer O
22:0;O2 O
and O
Cer O
24:0;O2 O
were O
less O
than O
0.1% O
of O
the O
those O
of O
their O
internal O
standards. O

For O
FA B-lipid
15:0 I-lipid
and O
18:2 O
lysoPC, O
their O
amount O
is O
high O
before O
reperfusion O
and O
their O
amount O
decreases O
considerably O
2 h O
post O
reperfusion. O

As O
arachidonic O
acid O
and O
FA B-lipid
22:6 I-lipid
are O
important O
molecules O
directly O
involved O
in O
pro-inflammatory O
responses O
through O
the O
COX O
and O
LOX O
pathways, O
the O
role O
of O
these O
molecules O
should O
be O
further O
elucidated O
in O
NHPs O
exposed O
to O
high O
levels O
of O
IR O
(e.g O
., O
10 O
Gy). O

Direct O
cortical O
mapping O
of O
abundant O
LPC B-lipid
18:0 I-lipid
revealed O
positive O
correlation O
with O
gray O
matter O
density O
mainly O
in O
right O
precentral O
gyrus, O
anterior O
cingulate O
areas, O
and O
medial O
parietal O
and O
occipital O
surfaces O
(Figure O
). O

LPC B-lipid
16:1, I-lipid
TG O
(46:4)A, O
TG B-lipid
42:3 I-lipid
and O
TG B-lipid
46:3 I-lipid
were O
statistically O
different O
in O
the O
meloxicam O
and O
saline-treated O
cats O
(p O
 = 0.002, O
0.017, O
0.012 O
and O
0.028, O
respectively). O

A O
striking O
observation O
was O
the O
total O
absence O
of O
long O
chain O
polyunsaturated O
fatty O
acids O
(LCPUFAs) O
in O
GGs O
of O
the O
retina O
and O
brain O
considering O
that O
these O
tissues O
contain O
very O
high O
amounts O
of O
LCPUFAs, O
especially O
FA B-lipid
22:6 I-lipid
(22:6 O
DHA): O
about O
20 O
and O
7% O
of O
total O
FAs O
in O
the O
retina O
and O
brain O
cerebrum, O
respectively. O

By O
contrast, O
neutral O
loading O
without O
acidification O
of O
the O
loading O
solution O
greatly O
improved O
recovery O
of O
13-H-9-E-LA O
(86.9 O
to O
107.1% O
across O
concentration O
range) O
and O
achieved O
good O
recoveries O
for O
all O
other O
analytes O
except O
FA B-lipid
20:3;Ep, I-lipid
although O
these O
acidic O
analytes O
would O
likely O
be O
charged O
at O
a O
neutral O
condition. O

, O
A O
higher O
amount O
of O
PE B-lipid
20:3/18:1 I-lipid
(p=0.094) O
was O
extracted O
with O
the O
methanol-ethanol O
precipitation O
compared O
to O
methanol O
only O
precipitation. O

A O
recent O
study O
was O
proposed O
that O
FA B-lipid
20:4(6,8,10,14);(OH)2 I-lipid
plays O
an O
important O
role O
in O
AML O
cell O
activation O
and O
proliferation, O
and O
it O
indicated O
that O
leukotriene O
biosynthesis O
inhibitors O
or O
antagonists O
similar O
to O
those O
employed O
in O
the O
treatment O
of O
asthma O
could O
be O
applicable O
in O
the O
treatment O
of O
AML. O

From O
, O
SM B-lipid
16:0;O2 I-lipid
and O
SM B-lipid
22:0;O2 I-lipid
were O
identified O
only O
in O
the O
extracts O
of O
protocols O
(i)–(iv), O
but O
could O
not O
be O
identified O
from O
protocols O
(v) O
and O
(vi). O

The O
highest O
significances O
(p < 10_−3 O
) O
were O
found O
for O
LPC B-lipid
20:0/0:0, I-lipid
ChoE(20:5), O
and O
ChoE(22:5), O
whose O
levels O
decreased O
in O
F2 O
patients O
when O
compared O
with O
F1. O

Plasma O
Cer B-lipid
22:0;O2 I-lipid
(a) O
and O
Cer B-lipid
24:0;O2 I-lipid
(b) O
were O
determined O
in O
two O
fasting O
samples O
obtained O
two O
weeks O
apart O
from O
each O
of O
14 O
human O
subjects O
(control, O
n O
= O
5; O
obese, O
n O
= O
5; O
and O
diabetic, O
n O
= O
4). O

FA B-lipid
18:2;OH I-lipid
and O
FA B-lipid
18:1;(OH)2 I-lipid
reduced O
VCAM-1 O
surface O
expression, O
whereas O
19, O
20-DiHDoPE O
did O
not O
alter O
VCAM-1 O
surface O
expression O
relative O
to O
TNFα. O

Tyrosine, O
glutamic O
acid, O
threonine, O
TCDCA, O
GCA, O
SM(1) B-lipid
18:0;3OH/14:0, I-lipid
SM(1) B-lipid
18:0;3OH/15:0, I-lipid
and O
SM(1) B-lipid
18:0;3OH/18:0, I-lipid
nervonic O
acid, O
24:1n-9, O
22:3n-x, O
and O
LPC B-lipid
0:0/16:1 I-lipid
increased O
in O
parallel O
with O
fibrosis O
stage. O

FA B-lipid
20:4(6,8,10,14);(OH)2 I-lipid
has O
a O
receptor O
with O
high O
specificity, O
B O
leukotriene O
receptor O
1 O
(BLT1), O
expressed O
exclusively O
in O
inflammatory O
cells O
such O
as O
neutrophils, O
macrophages O
and O
eosinophils. O

Adjusted O
OR O
(95% O
CI) O
of O
MI, O
IS, O
and O
ICH O
for O
Lipoprotein O
Particle O
Concentration, O
ST B-lipid
27:1;O, I-lipid
and O
Triglycerides O
as O
Measured O
by O
Nuclear Magnetic O
Resonance O
Spectroscopy O
Estimates O
are O
odds O
ratios O
(ORs) O
per O
1-SD O
higher O
metabolic O
marker. O

(P O
= O
0.011), O
uric O
acid O
(P O
= O
0.02), O
l-aspartyl-l-phenylalanine O
(P O
= O
0.0002), O
and O
lysoPCs O
containing O
C18:1 O
(P O
= O
0.037), O
C18:2 O
(P O
= O
0.045), O
C20:1 O
(P O
= O
0.008), O
and O
C20:4 O
(P O
= O
0.03), O
showed O
a O
significant O
increase O
during O
12 O
weeks O
of O
peptide O
intervention, O
whereas O
20 O
metabolites, O
that O
is, O
l-proline O
(P O
= O
0.003), O
valine O
(P O
= O
0.042), O
l-leucine/isoleucine O
(P O
= O
0.048), O
hypoxanthine O
(P O
= O
0.036), O
glutamine O
(P O
= O
0.028), O
l-methionine O
(P O
= O
0.039), O
phenylpyruvic O
acid O
(P O
= O
0.041), O
propionylcarnitine O
(P O
= O
0.05), O
butyrylcarnitine O
(P O
= O
0.05), O
l-hexanoylcarnitine O
(P O
= O
0.06), O
l-octanoylcarnitine O
(P O
= O
0.014), O
palmiotylcarnitine O
(P O
= O
0.034), O
linoleylcarnitine O
(P O
= O
0.02), O
and O
PCs O
containing O
C14:0 O
(P O
= O
0.045), O
PC B-lipid
16:0 I-lipid
(P O
= O
0.02), O
C15:0 O
(P O
= O
0.012), O
C16:0 O
(P O
= O
0.018), O
C17:1 O
(P O
= O
0.02), O
C18:0 O
(P O
= O
0.038), O
and O
C22:0 O
(P O
= O
0.029) O
showed O
decreased O
levels. O

These O
components O
included O
2-ethyl-5-methylfuran, O
3,4-dimethyl-2,5-furanedione, O
3,4-dehydro-β-ionone, O
FAL B-lipid
4:0;2Me, I-lipid
linalool, O
1,8-cineol, O
2-butanone, O
α-terpineol, O
tetrahydro-2,2,5,5-tetramethylfuran O
and O
FAL B-lipid
6:1(2). I-lipid

In O
the O
present O
study, O
significant O
differences O
in O
the O
concentration O
of O
FA B-lipid
10:0 I-lipid
were O
detected O
between O
the O
different O
subtypes O
of O
B-NHL. O

LOX-derived O
metabolites O
also O
contributed O
to O
the O
discrimination O
of O
subjects, O
including O
non-esterified O
alcohols O
such O
as O
5-hydroxy O
eicosapentaenoic O
acid O
(5-HEPE), O
FA B-lipid
18:4;OH, I-lipid
and O
FA B-lipid
18:2;OH. I-lipid

FA B-lipid
22:6 I-lipid
is O
an O
important O
structural O
component O
of O
the O
human O
brain, O
cerebral O
cortex, O
and O
the O
discs O
of O
the O
rod O
photoreceptor O
cells. O

The O
relative O
ion O
abundance O
of O
the O
sn O
-1 O
fragment O
of O
PC B-lipid
18:1/16:0 I-lipid
(m O
/z O
445) O
was O
normalized O
to O
the O
sum O
of O
sn O
-1 O
fragments O
of O
both O
isomers O
and O
plotted O
against O
corresponding O
concentrations O
(% O
mol). O

4-, O
7-, O
14- O
and O
FA B-lipid
22:6;17OH I-lipid
(4-HDHA, O
7-HDHA, O
14-HDHA, O
17-HDHA), O

Alanine O
and O
FA B-lipid
4:0;3OH I-lipid
also O
correlated O
to O
these O
three O
clinical O
measures, O
but O
the O
relation O
to O
glucose O
had O
a O
high O
q-value. O

The O
intensities O
and O
compositions O
of O
18 O
FFAs O
were O
also O
identified, O
and O
the O
intensities O
of O
FA B-lipid
16:2, I-lipid
18:3, O
18:4, O
and O
C22:5 O
were O
significantly O
lower O
in O
the O
recurrent O
AF O
group. O

 + SM(16:1/22:0), O
and O
two O
PC: O
PC B-lipid
16:0/16:0, I-lipid
and O
PC B-lipid
16:0/18:0. I-lipid

Abbreviations: O
High O
Density O
Lipoprotein O
ST B-lipid
27:1;O I-lipid
(HDL); O
Low O
Density O
Lipoprotein O
ST O
27:1;O O
(LDL); O
Viral O
load O
(VL) O
_a O
Computed O
using O
Mann-Whitney O
U O
test, O
corrected O
by O
Dunn-Sidak O
method O
_b O
Computed O
using O
the O
Kruskal-Wallis O
test, O
corrected O
by O
Benjamini-Hochberg O
method. O

HTG O
was O
defined O
according O
to O
the O
National O
ST B-lipid
27:1;O I-lipid
Education O
Program—Adult O
Treatment O
Panel O
III. O

In O
our O
analysis, O
FA B-lipid
4:0;3OH I-lipid
(aka O
beta-hydroxybutyrate O
(βOHB)) O
– O
hepatic O
ketone O
body O
– O
displayed O
a O
negative O
association O
with O
HOMA-IR. O

Briefly, O
urine O
samples O
were O
thawed O
at O
room O
temperature O
and O
centrifuged O
(at O
3000 g) O
for O
10 min O
and O
100 μ O
L O
urine O
samples O
(contained O
2.5 mmol/L O
creatinine) O
was O
first O
treated O
with O
30.0 μ O
L O
urease O
(1.2 U/μ O
L) O
at O
37°C O
for O
30 min O
to O
remove O
interfering O
urea O
and O
then O
spiked O
with O
FA B-lipid
17:0 I-lipid
(0.5 mg/mL, O
50 μ O
L). O

On O
the O
other O
hand, O
23 O
out O
of O
the O
30 O
(76.7%) O
BAV O
patients O
had O
ZS O
scores O
above O
the O
cutoff, O
followed O
by O
GNOE O
(23, O
76.7%), O
MG B-lipid
18:2 I-lipid
(23, O
76.7%), O
and O
PE B-lipid
18:2 I-lipid
(22, O
73.3%). O

LC-PB–MS/MS O
of O
e O
PE B-lipid
17:0_22:4 I-lipid
(RT: O
5.2 min, O
m/ O

The O
fold-difference O
of O
the O
known O
metabolites O
was O
calculated O
and O
three O
(threonine O
minor, O
FA B-lipid
4:0;2OH, I-lipid
N-acetyl-L-aspartic O
acid O
1) O
had O
a O
fold O
change O
greater O
than O
2, O
when O
comparing O
Cluster O
1 O
to O
Cluster O
2. O

For O
example, O
a O
biomarker O
panel O
including O
phenylacetic O
acid, O
l-fucose, O
caprylic O
acid, O
acetic O
acid, O
FA B-lipid
3:0 I-lipid
and O
glycine O
achieved O
good O
performance O
with O
the O
sensitivity O
of O
80% O
and O
specificity O
of O
100% O
for O
predicting O
small O
cell O
lung O
cancer. O

A O
total O
of O
2 O
volatile O
metabolites O
(FAL O
4:0;2Me I-lipid
and O
decanoic O
acid) O
were O
able O
to O
distinguish O
the O
patients O
with O
CD20_− O
B-NHL O
and O
CD20_+ O
B-NHL O
with O
significantly O
higher O
concentration O
levels O
in O
patients O
with O
CD20_− O
B-NHL. O

In O
UPLC-MS O
analyses, O
lysophos-phatidylethanolamine O
(lysoPE)(18:0) O
and O
lysophosphatidic O
acid(20:0) O
were O
higher O
in O
serum, O
and O
phosphatidylcholines O
(PC) O
(16:1/18:2, O
20:3/18:0, O
O-20:0/22:4), O
LPC B-lipid
16:0, I-lipid
PE B-lipid
O-18:2/20:4, I-lipid
sphingomyelin(18:0/22:0), O
and O
linoleic O
acid O
were O
lower. O

Alterations O
in O
phospholipid O
levels O
have O
been O
reported O
in O
pancreatic O
cancer O
patients, O
in O
whom O
LPC B-lipid
18:2 I-lipid
was O
downregulated, O
while O
upregulation O
of O
this O
metabolite O
was O
detected O
in O
the O
HFS O
group O
compared O
to O
the O
non-HFS O
group. O

Manual O
annotation O
indicates O
that O
the O
potentially O
novel O
oxylipin O
is O
identical O
to O
FA B-lipid
22:6;OH I-lipid
with O
the O
exception O
that O
it O
contains O
3 O
instead O
of O
4 O
double O
bonds O
between O
carbons O
11 O
and O
22. O

In O
muscle, O
Cer B-lipid
18:1;O2/18:0 I-lipid
was O
the O
only O
lipid O
higher O
in O
insulin O
resistance O
independent O
of O
overweight/obesity. O

Arachidonic O
acid-derived O
eicosanoids O
12-HETE O
and O
FA B-lipid
20:4;OH, I-lipid
several O
γ-glutamyl O
peptides, O
cell O
turnover O
metabolite O
sphingosine, O
amino O
acids O
serine O
and O
glycine, O
and O
several O
acylcarnitines O
were O
most O
significantly O
associated O
with O
HCC. O

Next, O
TCDCA, O
taurocholic O
acid O
(TCA), O
and O
PC B-lipid
16:0/16:0 I-lipid
were O
the O
most O
significant O
metabolites O
in O
F3 O
patients O
when O
compared O
with O
F2. O

Among O
the O
statistically O
significant O
correlations, O
lauric O
acid O
(C12:0), O
FA B-lipid
15:0 I-lipid
(C15:0), O
stearic O
acid O
(C18:0), O
myristoleic O
acid O
(C14:1), O
cis-10 O
FA O
15:0 O
(C15:1) O
and O
arachidonic O
acid O
(C20:4n6) O
were O
stronger O
correlated O
in O
the O
case O
than O
the O
control O
group O
(p O
< O
0.001). O

collision O
energy O
12 O
eV, O
8iPGF_3 O
351.0 O
->193.0, O
collision O
energy O
22 O
eV, O
20-COOH-LTB_4 O
365.0 O
->195.0, O
collision O
energy O
13 O
eV, O
RvD1, O
RvD2 O
375.0 O
->141.3, O
collision O
energy O
13 O
eV; O
RvE1 O
375.1 O
->141.3, O
collision O
energy O
13 O
eV; O
from O
9.0–12.5 O
min O
for O
FA B-lipid
18:2;OH I-lipid
294.7 O
->170.7, O
collision O
energy O
16 O
eV; O
FA O
18:2;OH O
294.7 O
->194.7, O
collision O
energy O
16 O
eV; O
FA B-lipid
20:5;OH I-lipid
317.0 O
->115.0, O
collision O
energy O
17 O
eV; O
FA O
20:5;OH O
317.0 O
->179.0, O
collision O
energy O
17 O
eV; O
FA O
20:5;OH O
317.0 O
->219.0, O
collision O
energy O
17 O
eV, O
LTC_4 O
623.9 O
->272.0, O
collision O
energy O
14 O
eV O
from O
12.5–16.0 O
min O
for O
LA O
279.3 O
->279.0, O
collision O
energy O
10 O
eV; O
8-HEPE O
317.0 O
->255.0, O
collision O
energy O
17 O
eV, O
FA O
20:5;OH O
317.0 O
->259.0, O
collision O
energy O
17 O
eV; O
5-oxoETE, O
12-oxoETE O
and O
15-oxoETE O
317.0 O
->273.0, O
collision O
energy O
17 O
eV, O
FA B-lipid
20:4;OH I-lipid
319.0 O
>245.0, O
collision O
energy O
10 O
eV; O
LTC_4 O
623.9 O
->272.0, O
collision O
energy O
14 O
eV; O
LTE_4 O
438.0 O
->333.0, O
collision O
energy O
13 O
eV O
from O
12.5–16.0 O
min O
for O
LA O
279.3 O
->59.2, O
collision O
energy O
25 O
eV; O
EPA O
301.0 O
->203.2, O
collision O
energy O
12 O
eV; O
AA O
303.0 O
->259.3, O
collision O
energy O
11 O
eV, O
DHA O
327.1 O
->29.3, O
collision O
energy O
14 O
eV. O
Method O
B O
from O
0.0–9.8 O
min O
for O
PGE_2 O
, O
d15d12PGD_2 O
, O
PGD_2 O
, O
d15d12PGJ_2 O
, O
PGJ_2 O
315.0 O
->271.3, O
collision O
energy O
13 O
eV; O
LTB_5 O
333.0 O
->195.0, O
collision O
energy O
13 O
eV; O
LTB_4 O
335.0 O
->195.0, O
collision O
energy O
13 O
eV; O
RvE_1 O
349.1 O
->195.3, O
collision O
energy O
13 O
eV; O
HXA_3 O
, O
HXB_3 O
, O
20-COOH-AA O
335.0 O
->273.3, O
collision O
energy O
13 O
eV; O
LXA_5 O
349.0 O
->115.0, O
collision O
energy O
12 O
eV; O
20-OH-LTB_4 O
351.0 O
->195.0, O
collision O
energy O
13 O
eV; O
MaR O
359.0 O
->250.0, O
collision O
energy O
13 O
eV; O
from O
9.8–12.5 O
min O
for O
FA O
20:4;OH O
318.7 O
->115.0, O
collision O
energy O
14 O
eV; O
FA O
20:4;OH O
319.0 O
->155.0, O
collision O
energy O
14 O
eV; O
FA O
20:4;OH O
319.0 O
->167.0, O
collision O
energy O
14 O
eV; O
FA O
20:4;OH O
319.0 O
->179.0, O
collision O
energy O
14 O
eV; O
FA O
20:4;OH O
319.0 O
->218.9, O
collision O
energy O
11 O
eV; O
4-HDHA O
343.0 O
->101.0, O
collision O
energy O
10 O
eV; O
10-HDHA O
343.0 O
->181.0, O
collision O
energy O
10 O
eV; O
14-HDHA O
343.0 O
->205.0, O
collision O
energy O
10 O
eV; O
17-HDHA O
343.0 O
->245.0, O
collision O
energy O
14 O
eV, O
20-HDHA O
343.0 O
->285.0, O
collision O
energy O
10 O
eV; O
13-oxoODE O
293.0 O
->249.0, O
collision O
energy O
17 O
eV O
and O
from O
12.5–16.0 O
min O
for O
LA O
279.3 O
->59.2, O
collision O
energy O
25 O
eV; O
EPA O
301.0 O
->203.2, O
collision O
energy O
12 O
eV, O
AA O
303.0 O
->259.3, O
collision O
energy O
11 O
eV, O
DHA O
327.1 O
->229.3, O
collision O
energy O
14 O

As O
we O
were O
able O
to O
detect O
slightly O
higher O
levels O
of O
the O
COX-2 O
byproducts, O
FA B-lipid
20:4;OH, I-lipid
13-HDHA, O
and O
17-HDHA, O
in O
individuals O
under O
statin O
treatment O
compared O
with O
untreated O
or O
ASA-treated O
subjects, O
there O
could O
be O
a O
combined O
effect O
of O
statin O
treatment O
to O
induce O
COX-2 O
expression O
and O
activation O
by O
S-nitrosylation O
leading O
to O
increased O
formation O
of O
FA O
20:4;OH, O
13-HDHA, O
and O
17-HDHA O
(, O
, O
). O

Three O
metabolites O
were O
identified O
that O
contributed O
to O
the O
group O
separation O
in O
both O
studies: O
FA B-lipid
4:0;3OH,4OH, I-lipid
FA B-lipid
22:5, I-lipid
and O
uric O
acid. O

Proportional O
amounts O
of O
LPC B-lipid
15:0 I-lipid
were O
positively O
associated O
with O
both O
TC O
(r O
= O
0.64, O
p O
= O
0.004) O

Cao O
et O
al O
revealed O
that O
the O
levels O
of O
LPC O
(FA O
P-18:0) I-lipid
and O
LPC O
(FA O
P-16:0) I-lipid
were O
higher O
in O
patients O
with O
HCC O
compared O
that O
of O
healthy O
controls, O
consistent O
with O
the O
current O
study. O

Similarly, O
a O
positive O
correlation O
was O
observed O
between O
plasma O
FA B-lipid
20:4;OH I-lipid
and O
plasma O
concentration O
of O
homocysteine O
(r O
_s O
=0.503; O
P O
=0.005) O
and O
creatinine O
(r O
_s O
=0.460; O
P O
<0.02). O

New O
SM O
molecules O
were O
most O
probably O
generated O
from O
degraded O
PC O
compounds O
by O
SM O
synthase O
(this O
transferase O
utilizes O
a O
choline O
“head” O
from O
PC) O
and O
suitable O
ceramide O
molecules, O
which O
was O
coherent O
with O
observed O
down-regulation O
of O
Cer B-lipid
36:2;O2. I-lipid

Further O
studies O
are O
needed O
to O
compare O
patients O
with O
stable O
carotid O
plaque O
vs. O
patients O
with O
unstable O
carotid O
plaque O
in O
order O
to O
confirm O
that O
FA B-lipid
20:4;OH I-lipid
could O
be O
a O
potential O
factor O
related O
to O
carotid O
plaque. O

The O
Cer B-lipid
22:0;O2 I-lipid
and O
Cer B-lipid
24:0;O2 I-lipid
in O
standard O
curve O
matrix O
and O
stock O
solution O
were O
stable O
for O
4 O
hours O
at O
room O
temperature O
and O
for O
38 O
days O
at O
−80 O
°C O
(see O
). O

ROC O
curves O
of O
volatile O
biomarkers O
for O
the O
diagnosis O
of O
(A) O
B-NHL O
from O
non-lymphoma, O
(B) O
B-NHL O
from O
healthy O
control, O
(C) O
aggressive O
B-NHL O
from O
indolent O
B-NHL, O
(D) O
CD20_+ O
B-NHL O
from O
CD20_− O
B-NHL, O
(E) O
early-stage O
B-NHL O
from O
advanced O
B-NHL O
using O
different O
combinations O
of O
4-heptanone, O
2-methylpyrazine, O
FAL B-lipid
4:0;2Me, I-lipid
2,6-dimethyl-7-octen-2-ol O
and O
FA B-lipid
10:0. I-lipid

20-OH-LTB_4 O
(P O
 = 0.048), O
FA B-lipid
20:4;OH I-lipid
(P O
 = 0.017), O
5-oxoETE O
and O
from O
the O
15-LOX O
pathways, O
FA O
20:4;OH O
(P O
 = 0.004), O
15-oxoETE O
and O
17-HDHA, O
were O
found O
in O
higher O
concentrations O
in O
AgP O
patients. O

Parts O
of O
the O
peaks O
were O
identified O
as O
1, O
lactic O
acid; O
2, O
alanine; O
3, O
valine; O
4, O
leucine; O
5, O
proline; O
6, O
glycine; O
7, O
uracil; O
8, O
fumaric O
acid; O
9, O
serine; O
10, O
threonine; O
11, O
malic O
acid; O
12, O
pyroglutamic O
acid; O
13, O
asparagine; O
14, O
hydroxyproline; O
15, O
creatinine; O
16, O
ornithine; O
17, O
glutamic O
acid; O
18, O
phenylalanine; O
19, O
ribose; O
20, O
glutamine; O
21, O
hypoxanthine; O
22, O
glucose; O
23, O
FA B-lipid
16:0; I-lipid
24, O
linoleic O
acid; O
25, O
oleic O
acid; O
26, O
tryptophan; O
27, O
stearic O
acid; O
28, O
glucose-6-phosphate; O
29, O
maltose; O
and O
30, O
cholesterol. O

From O
those, O
SM B-lipid
18:2;O2/18:1 I-lipid
and O
PC(trans O
18:1/22:6) O
may O
be O
a O
general O
plasma O
marker O
of O
exposure O
to O
TFAs. O

The O
metabolites O
were O
ChoE(18:1), O
ChoE(18:2), O
ChoE(20:4), O
PE B-lipid
16:0/18:1, I-lipid
SM B-lipid
18:1;O2/23:0, I-lipid
SM B-lipid
42:3;O2 I-lipid
and O
TG B-lipid
54:1 I-lipid
and O
the O
model O
was: O

All-ions O
CID O
at O
this O
retention O
time O
confirms O
the O
acyl O
chain O
composition O
of O
the O
glycerophospholipid O
as O
PC B-lipid
18:0_18:1, I-lipid
and O
the O
observation O
of O
two O
pairs O
of O
OzID O
product O
ions O
reveals O
a O
mixture O
of O
the O
double O
bond O
isomers O
PC O
18:0_18:1(n O
-7) O
and O
PC O
18:0_18:1(n O
-9). O

A O
stable O
FA B-lipid
20:4;OH I-lipid
agonist O
5(Z),14(Z)-20-HEDE O
(WIT003) O
was O
synthesized O
by O
Dr. O
John O
R O
Falck O
(University O
of O
Texas O
Southwestern). O

It O
was O
also O
challenging O
to O
compare O
the O
TLC/GC-FID O
lipid O
results O
with O
the O
GC-MS O
results O
as O
the O
two O
methods O
only O
identified O
and O
quantified O
8 O
metabolites O
in O
common O
(arachidonic O
acid, O
FA B-lipid
20:0, I-lipid
linoleic O
acid, O
oleic O
acid, O
palmitelaidic O
acid, O
palmitic O
acid, O
stearic O
acid O
and O
tetradecanoic O
acid). O

FA B-lipid
10:0 I-lipid
was O
detected O
in O
several O
types O
of O
fats O
and O
may O
be O
responsible O
for O
the O
mitochondrial O
proliferation O
associated O
with O
the O
ketogenic O
diet O
(,). O

Among O
the O
lipids O
investigated, O
fewer O
than O
ten O
correlations O
were O
found O
for O
LPC O
14:0 O
(8), O
PC B-lipid
26:0 I-lipid
(7), O
PC B-lipid
36:0 I-lipid
(5), O
PC B-lipid
40:1 I-lipid
(9), O
GPCe O
42:0 O
(5), O
GPCe O
42:5 O
(7), O
GPCe O
44:5 O
and O
SM B-lipid
22:3;O2 I-lipid
(2). O

LPA B-lipid
17:0 I-lipid
was O
used O
as O
an O
internal O
standard. O

All O
definitions O
were O
obtained O
from O
the O
National O
ST B-lipid
27:1;O I-lipid
Education O
Program's O
Adult O
Treatment O
Panel O
III O
report O
. O

Measurements O
were O
performed O
in O
two O
subsets O
of O
the O
total O
study O
population O
in O
the O
ST B-lipid
27:1;O I-lipid
and O
Pharmacogenetics O
(CAP) O
study: O
Full O
Range O
of O
Response O
(FR), O
and O
Good O
and O
Poor O
Responders O
(GPR) O
were O
100 O
individuals O
randomly O
selected O
from O
across O
the O
entire O
range O
of O
LDL-C O
responses O
in O
CAP. O

Furthermore, O
the O
increase O
of O
pyruvate O
could O
be O
mediated O
through O
the O
methylcitrate O
cycle O
(MCC), O
which O
oxidizes O
CoA B-lipid
3:0 I-lipid
generated O
by O
β-oxidation O
of O
odd-chain O
fatty O
acids O
to O
pyruvate O
, O
which O
then O
feed O
into O
the O
TCA O
cycle O
_, O
. O

Using O
PC B-lipid
34:1 I-lipid
as O
an O
example, O
MS_2 O
CID O
of O
[M O
+ O
HCO_3 O
]_– O
(m O
/z O
820) O
suggested O
that O
it O
contained O
94% O
PC B-lipid
16:0/18:1 I-lipid
and O
6% O
PC B-lipid
18:1/16:0. I-lipid

We O
retrieved O
10 O
μL O
of O
serum O
and O
added O
water/methanol/dichloromethane O
at O
room O
temperature O
with O
2:2:2 O
volume O
ratio, O
followed O
by O
spiking O
internal O
standards O
PC B-lipid
17:0/17:0, I-lipid
LPC O
17:0, O
PG B-lipid
17:0/17:0, I-lipid
PE B-lipid
17:0/17:0, I-lipid
TG B-lipid
17:0/17:0/17:0, I-lipid
SM B-lipid
18:1;O2/17:0, I-lipid
MAG O
17:0, O
DG B-lipid
16:0_18:1, I-lipid
CE O
17:0, O
ceramide O
phosphate O
18:1/17:0, O
PA O
17:0, O
PI B-lipid
17:0/20:4, I-lipid
and O
PS B-lipid
17:0/17:0. I-lipid

In O
our O
study, O
the O
decreased O
levels O
of O
LPC B-lipid
18:2 I-lipid
in O
AOSD O
patients O
may O
indicate O
its O
potential O
protective O
effect O
aganst O
inflammatory O
response O
and O
suggest O
its O
augmented O
consumption O
in O
apopotic O
processes O
in O
this O
disease. O

For O
the O
UPLC-MS O
measurements, O
run O
in O
triplicate, O
we O
calculated O
analytical O
variation O
(CVa); O
the O
range O
was O
1.8% O
(PC O
P-16:0/20:4) I-lipid
to O
60.5% O
(LPE O
18:0). I-lipid

Significant O
metabolites O
according O
to O
the O
jack-knife O
confidence O
intervals O
were: O
LPCs O
(14:0), O
(16:0), O
(16:1), O
(18:1), O
(18:3), O
(20:4), O
(20:3); O
phospchocholines: O
(30:1), O
(32:1), O
(32:2), O
(34:2), O
(34:4), O
(FA O
O-34:3) I-lipid
and O
sphingomyelins: O
(33:1), O
(32:1), O
(38:1), O
(39:1). O

The O
AUC O
values O
of O
MG B-lipid
18:2, I-lipid
GNOE, O
PE B-lipid
18:2 I-lipid
and O
ZS O
in O
the O
validation O
group O
were O
0.815, O
0.793, O
0.738 O
and O
0.930, O
respectively, O
which O
were O
all O
similar O
to O
their O
counterparts O
in O
the O
estimation O
group. O

FA B-lipid
20:4;20OH I-lipid
(20-HETE), O
a O
metabolite O
of O
arachidonic O
acid O
(AA) O
produced O
by O
the O
CYP4A O
and O
CYP4F O
enzyme O
families O
has O
been O
reported O
to O
induce O
mitogenic O
and O
angiogenic O
responses O
both O
in O
vitro O
and O
in O
vivo, O
and O
inhibitors O
of O
this O
pathway O
reduced O
growth O
of O
brain O
and O
kidney O
tumors. O

9H-purine, O
creatinine, O
and O
FA B-lipid
4:0 I-lipid
are O
considered O
to O
have O
“tentative O
identification” O
because O
their O
identity O
was O
determined O
with O
an O
external O
mass O
spectral O
library O
instead O
of O
matching O
both O
retention O
time O
and O
mass O
spectra O
to O
the O
in-house O
library O
of O
standards. O

Hence, O
we O
concluded O
the O
identification O
for O
the O
species O
with O
neutral O
mass O
of O
755.5465 O
Da O
with O
the O
retention O
time O
of O
9.61 O
min O
to O
be O
PC B-lipid
16:1/18:2. I-lipid

As O
shown O
in O
, O
the O
mean O
concentrations O
for O
a O
number O
of O
these O
metabolites O
including O
formate, O
histidine, O
proline, O
N-acetyl-glycine O
and O
FA B-lipid
4:0;2Me;3OH I-lipid
decrease O
significantly O
in O
recurrent O
cancer. O

FA B-lipid
4:0;2OH I-lipid
(2-HBA) O
is O
derived O
from O
α-ketobutyrate O
as O
a O
byproduct O
of O
GSH O
anabolism O
when O
cystathionine O
is O
converted O
to O
cysteine. O

In O
detail, O
the O
aspartate O
(Asp), O
citrulline O
(Cit), O
glycine O
(Gly), O
histidine O
(His), O
lysine O
(Lys), O
methionine O
(Met), O
ornithine O
(Orn), O
tryptophan O
(Trp), O
valine O
(Val) O
and O
etherphosphorylcholine O
(GPCe) O
42:4 O
levels O
in O
sperm O
cells O
and O
the O
acetylornithine O
(Ac-Orn), O
phenethylamine O
(PEA), O
phosphatidylcholine O
(PC) O
30:2 O
and O
PC B-lipid
38:1 I-lipid
levels O
in O
seminal O
plasma O
were O
not O
included O
in O
the O
correlation O
analyses. O

ST B-lipid
27:1;O I-lipid
levels O
are O
largely O
controlled O
by O
the O
liver, O
which O
is O
the O
major O
source O
of O
cholesterol O
and O
LDL O
via O
very O
low-density O
lipoprotein O
(VLDL) O
production, O
and O
also O
the O
major O
site O
of O
LDL O
catabolism. O

Increased O
levels O
of O
FA B-lipid
9:0;COOH I-lipid
were O
detected O
in O
the O
present O
study, O
and O
may O
represent O
evidence O
that O
this O
oxidative O
attack O
can O
occur O
in O
a O
prediabetic O
state. O

The O
metabolites O
FA B-lipid
20:5;OH I-lipid
and O
FA O
20:5;OH O
are O
produced O
via O
the O
LOX O
pathway, O
but O
with O
EPA O
as O
precursor O
fatty O
acid. O

MS/MS O
spectra O
of O
the O
earlier O
eluting O
isomer O
of O
PC B-lipid
40:6 I-lipid
implied O
contribution O
of O
two O
species O
(PC O
18:1/22:5 I-lipid
and O
PC B-lipid
20:2/20:4) I-lipid
to O
a O
single O
chromatographic O
peak. O

Statistically O
significant O
differences O
were O
observed O
in O
plasma O
concentration O
(A) O
and O
urinary O
excretion O
(B O
and O
C) O
of O
FA B-lipid
20:4;OH I-lipid
between O
patients O
with O
RVD O
and O
healthy O
control O
subjects. O

Moreover, O
high O
levels O
of O
Lp-PLA2 O
and O
LPC B-lipid
16:0 I-lipid
are O
associated O
with O
symptomatic O
carotid O
plaques. O

This O
occurred O
alongside O
an O
increased O
TG B-lipid
52:4 I-lipid
(CHEBI: O
84660) O
and O
in O
the O
most O
abundant O
non-esterified O
fatty O
acids O
within O
adipose O
tissue. O

In O
seminal O
plasma, O
SM O
16:0, O
PC B-lipid
34:1 I-lipid
and O
SM O
24:0 O
were O
present O
at O
the O
highest O
concentrations O
of O
all O
lipids O
investigated. O

In O
plasma, O
insulin O
resistance O
was O
aligned O
with O
higher O
TG B-lipid
16:0_16:0_16:0, I-lipid
DG B-lipid
14:0_16:0, I-lipid
DG B-lipid
16:0_16:0, I-lipid
DG B-lipid
16:0_18:0, I-lipid
and O
DG B-lipid
16:0_20:4, I-lipid
SE B-lipid
27:1/16:1 I-lipid
and O
SE B-lipid
27:1/20:4 I-lipid
and O
lower O
LPC B-lipid
20:0, I-lipid
LPC B-lipid
20:1, I-lipid
LPC B-lipid
22:1, I-lipid
LPC(O‐20:0) O
and O
LPC(O‐22:1) O

Relapsing O
Remitting O
Multiple O
Sclerosis; O
SPMS: O
Secondary O
Progressive O
Multiple O
Sclerosis; O
VLCFA: O
Very O
Long O
Chain O
Fatty O
Acids; O
GTA: O
Gastrointestinal O
Tract O
Acids; O
DHA: O
FA B-lipid
22:6 I-lipid
Altered O
mitochondrial O
structure, O
molecular O
and O
biochemical O
abnormalities, O
impaired O
Complex O

FA B-lipid
17:0 I-lipid
(C17:0) O
belongs O
to O
the O
odd-chain O
fatty O
acids, O
and O
although O
it O
has O
been O
widely O
used O
as O
a O
biomarker O
of O
dairy O
intake O
(Yakoob O
et O
al., O
), O
there O
is O
recent O
evidence O
that O
it O
is O
related O
to O
metabolic O
diseases O
and O
gut O
microbiome O
imbalance O
(Jenkins O
et O
al., O
). O

Elderly O
women O
had O
higher O
concentration O
of O
FA B-lipid
18:2;OH I-lipid
and O
2,3-dinor-8-iso-PGF_2α O
than O
other O
groups O
(a O
and O
b). O

Liquid O
chromatography/mass O
spectrometry O
analysis O
(LC-MS/MS) O
was O
performed O
to O
measure O
FA B-lipid
20:4;OH I-lipid
formation O
in O
tumor O
homogenates. O

Furthermore, O
FA B-lipid
4:0;2OH I-lipid
(α-hydroxybutyrate; O
AHBA) O
shows O
the O
lowest O
p O
-value O
of O
all O
metabolites O
between O
control O
and O
GDM O
and O
therefore O
is O
one O
of O
the O
strongest O
metabolic O
alterations O
(Supplementary O
Figure O
). O

For O
CYP450 O
related O
compounds O
of O
the O
AA-pathway, O
FA B-lipid
20:3;(OH)2 I-lipid
and O
FA O
20:3;(OH)2 O
were O
found O
to O
be O
present O
at O
higher O
levels O
than O
FA O
20:3;(OH)2 O
and O
FA O
20:3;(OH)2. O
Epoxides O
of O
the O
AA-pathway O
were O
below O
the O
detection O
limit O
and O
thus O
not O
detected O
in O
these O
samples. O

While O
FAL B-lipid
15:2(2,6);OH I-lipid
in O
Fig. O

In O
general, O
the O
abundances O
of O
LPC B-lipid
16:1 I-lipid
and O
PC B-lipid
33:1 I-lipid
were O
higher O
in O
the O
meloxicam O
group O
than O
those O
in O
the O
control O
group. O

In O
the O
patient O
group O
with O
highly O
active O
MS, O
FA B-lipid
20:4;OH I-lipid
and O
PGE_2 O
were O
increased, O
which O
are O
products O
of O
the O
15-lipoxygenase O
and O
cyclooxygenase O
pathways. O

PC O
cleavage O
can O
also O
be O
performed O
by O
PLD O
to O
generate O
PA, O
such O
as O
the O
PA B-lipid
32:0 I-lipid
and O
PA B-lipid
O-31:2 I-lipid
found O
in O
this O
study. O

MS/MS O
fragmentation O
of O
PC B-lipid
40:7 I-lipid
lead O
to O
its O
identification O
as O
PC B-lipid
18:1/22:6 I-lipid
based O
on O
the O
fragment O
ions O
550.3 O
([M+Li-R1′CHCO]+) O
and O
556.3 O
([M+Li-R1CO2Li]+). O

The O
CV O
of O
each O
metabolite O
was O
as O
follows: O
tetradecane O
(−1.14783E-05), O
alpha-D-glucopyranoside O
(−4.47826E-06), O
methyl O
stearate O
(−6.08696E-06), O
dodecane O
(−7.6087E-06), O
1-4-benzene O
(1.44348E-05), O
D-galactose O
(−2.6087E-06) O
and O
FA B-lipid
18:0 I-lipid
(1.02609E-05). O

To O
this, O
750 µl O
methyl O
tert-butyl O
ether O
(MTBE) O
was O
added, O
along O
with O
150 µl O
of O
internal O
standard O
mix, O
containing O
the O
following O
six O
internal O
standards: O
1,2-di-o-octadecyl-sn-glycero-3-phosphocholine O
(0.6 µM), O
1,2-di-O-phytanyl-sn-glycero-3-phosphoethanolamine O
(1.2 µM), O
C8-ceramide O
(0.6 µM), O
N-heptadecanoyl-D-erythro-sphingosylphosporylcholine O
(0.6 µM), O
FA B-lipid
11:0 I-lipid
(0.6 µM), O
and O
trilaurin O
(0.6 µM). O

It O
was O
further O
suggested O
from O
this O
study O
that, O
at O
least O
for O
patients O
with O
slowly O
proliferating O
tumour O
cells, O
the O
balance O
between O
FA B-lipid
20:4(6,8,10,14);(OH)2 I-lipid
synthesis O
and O
inactivation O
can O
be O
constant. O

None O
of O
the O
analyzed O
samples O
contained O
signals O
representing O
a O
relevant O
interference O
with O
the O
selected O
internal O
standards O
(IS) O
DG O
40:0, O
TG B-lipid
51:0, I-lipid
and O
TG B-lipid
57:0 I-lipid
(ESM O
Fig. O

ST B-lipid
27:1;O I-lipid
in O
large O
HDL O
was O
inversely O
associated O
with O
MI O
and O
IS O
(OR: O
0.79 O
and O
0.88, O
respectively), O
whereas O
cholesterol O
in O
small O
HDL O
was O
not O
(OR: O
0.99 O
and O
1.06, O
respectively). O

Interestingly, O
several O
other O
members O
of O
cluster O
1 O
contain O
the O
omega-3 O
fatty O
acid, O
FA B-lipid
22:6 I-lipid
(DHA, O
C22:6) O
although O
some O
also O
contain O
the O
omega-6 O
fatty O
acid, O
arachidonic O
acid O
(AA, O
C20:4). O

ROC O
curves O
for O
the O
combination O
of O
FA B-lipid
5:0;4OH, I-lipid
5-dihydrotestosterone O
sulfate, O
serine, O
spermine, O
and O
xanthine. O

The O
significant O
fold O
change O
was O
LPC B-lipid
20:0 I-lipid
(fold-change O
= O
4.08). O

Finally, O
an O
analysis O
of O
the O
postprandial O
behavior O
of O
candidate O
FIBs, O
in O
particular O
the O
dairy O
fatty O
acids O
pentadecanoic O
acid O
and O
FA B-lipid
17:0, I-lipid
revealed O
specific O
kinetic O
patterns O
of O
relevance O
to O
their O
detection O
in O
future O
validation O
studies. O

Representative O
MRM O
chromatogram O
of O
FA B-lipid
20:4;OH, I-lipid
PGE_2 O
and O
RvD1 O
from O
patients O
with O
less O
active O
MS O
(black O
line) O
and O
with O
highly O
active O
MS O
(red O
line). O

Chief O
among O
them O
are O
several O
GPLs O
that O
are O
believed O
to O
have O
biological O
significance O
in O
cancer O
physiology, O
including O
PC B-lipid
32:1, I-lipid
PC B-lipid
34:1, I-lipid
PS B-lipid
38:5, I-lipid
PE B-lipid
38:6, I-lipid
PC B-lipid
32:3, I-lipid
and O
PC(34:2)._5 O
, O

Taken O
together, O
these O
data O
suggest O
that O
SM B-lipid
36:1;O2, I-lipid
SM B-lipid
38:1;O2 I-lipid
and O
SM B-lipid
40:1;O2 I-lipid
among O
lipid O
species O
might O
be O
putative O
diagnostic O
markers O
in O
pre-diabetic O
patients O
with O
AO. O

Plasma O
(100 O
μl) O
was O
combined O
in O
10 O
ml O
glass O
tubes O
with O
internal O
standard O
solution O
(100 O
μl) O
composed O
of O
FA B-lipid
17:0 I-lipid
(200 O
μg/ml O
in O
hexane O
containing O
0.01% O
BHT), O
vortex O
mixed O
for O
5 O
s, O
and O
then O
reduced O
to O
dryness O
under O
a O
gentle O
stream O
of O
nitrogen O
at O
room O
temperature. O

In O
this O
study, O
we O
found O
no O
suppression O
of O
FA B-lipid
20:4;OH, I-lipid
17- O
HDHA, O
and O
FA B-lipid
20:5;OH I-lipid
levels O
in O
the O
colon O
mucosa O
of O
ASA-treated O
individuals O
compared O
with O
untreated O
subjects, O
while O
FA O
20:4;OH, O
FA B-lipid
18:2;OH, I-lipid
and O
13-HDHA O
levels O
were O
significantly O
lower, O
comparable O
to O
the O
observed O
decrease O
in O
prostanoid O
levels. O

A O
trend O
toward O
higher O
5- O
and O
12-lipoxygenation O
and O
lower O
15-lipoxygenation O
products O
and O
FA B-lipid
20:5;OH I-lipid
in O
peritonitis O
could O
be O
observed O
with O
high O
inter-individual O
variation, O
while O
for O
SPMs O
no O
consistent O
trend O
toward O
an O
elevation O
or O
reduction O
in O
peritonitis O
was O
observed. O

Our O
study O
found O
that O
esters O
of O
short O
chain O
fatty O
acids, O
cyclohexanecarboxylic O
acid O
and O
its O
derivatives O
were O
present O
in O
increased O
abundance O
in O
the O
feces O
of O
IBS-D O
patients O
compared O
with O
active O
IBD, O
while O
fecal O
aldehydes, O
such O
as O
FAL B-lipid
7:0 I-lipid
and O
FAL B-lipid
3:0, I-lipid
were O
more O
abundant O
in O
active O
CD O
(p<0.05). O

CYP O
monooxygenases O
are O
expressed O
in O
the O
renal O
vasculature O
and O
nephron, O
generating O
primarily O
FA B-lipid
20:4;20OH I-lipid
(20-HETE) O
by O
ω O
- O
and O
ω O
-1 O
hydroxylases O
and O
5,6-, O
8,9-, O
11,12-, O
and O
14,15-epoxyeicosatrienoic O
acids O
(EETs) O
by O
epoxygenases. O

